Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: A prospective, multicentre, UK study

Health Technology Assessment

Volumn 17, Issue 51, 2013, Pages 1-141

  Olson, J ^a   Sharp, P ^b   Goatman, K ^b   Prescott, G ^b   Scotland, G ^b   Fleming, A ^b   Philip, S ^c   Santiago, C ^d   Borooah, S ^e   Broadbent, D ^f   Chong, V ^g   Dodson, P ^h   Harding, S ⁱ   Leese, G ^j   Styles, C ^k   Swa, K ^l   Wharton, H ^h  

^a University of Aberdeen ^*

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Woolmanhill Hospital   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e PRINCESS ALEXANDRA EYE PAVILION   (United Kingdom)

^f ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^g OXFORD EYE HOSPITAL   (United Kingdom)

^h BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j NINEWELLS HOSPITAL   (United Kingdom)

^k QUEEN MARGARET HOSPITAL   (United Kingdom)

^l INFORMATION SERVICES DIVISION   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE MARKER; ECONOMIC EVALUATION; EYE PHOTOGRAPHY; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; PREVALENCE; PROSPECTIVE STUDY; QUALITY OF LIFE; RETINA MACULA EDEMA; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM; VISUAL ACUITY;

ADULT; AUTOMATION; BIOLOGICAL MARKERS; DIABETIC RETINOPATHY; FEMALE; GREAT BRITAIN; HUMANS; MACULAR EDEMA; MALE; MASS SCREENING; PHOTOGRAPHY; PROSPECTIVE STUDIES; QUALITY IMPROVEMENT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE;

EID: 84887796506     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta17510     Document Type: Article

References (91)

1. Goatman KA. A reference standard for the measurement of macular oedema. Br J Ophthalmol 2006;90:1197-1202. http://dx.doi.org/10.1136/bjo.2006.095885
2. Facey K, Cummins E, Macpherson K, Morris A, Reay L, Slattery J. Organisation of services for diabetic retinopathy screening. Health Technology Assessment report 1. Glasgow: Health Technology Board for Scotland; 2002.
3. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular oedema: pathogenesis and treatment. Surv Ophthalmol 2009;54:1-32.
4. Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris F. Detection of diabetic macular oedema. Ophthalmoscopy versus photography - Early Treatment Diabetic Retinopathy Study Report Number 5. The ETDRS Research Group. Ophthalmology 1989;96:746-750; discussion 750-751.
5. Bresnick GH, Mukamel DB, Dickinson JC, Cole DR. A screening approach to the surveillance of patients with diabetes for the presence of vision-threatening retinopathy. Ophthalmology 2000;107:19-24. http://dx.doi.org/10.1016/S0161-6420(99)00010-X
6. Sanchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-Montanes J, Garcia-Layana A. Retinal thickness study with optical coherence tomography in patients with diabetes. Invest Ophthalmol Vis Sci 2002;43:1588-1594.
7. Massin P, Girach A, Erginay A, Gaudric A. Optical coherence tomography: a key to the future management of patients with diabetic macular oedema. Acta Ophthalmol Scand 2006;84:466-474. http://dx.doi.org/10.1111/j.1600-0420.2006.00694.x
8. Hee MR, Puliafito C, Duker JS, Reichel E, Coker JG, Wilkins JR, et al. Topography of diabetic macular oedema with optical coherence tomography. Ophthalmology 1998;105:360-370.
9. Strom C. Comparison of objective retinal thickness analysis and subjective stereo fundus photography in diabetic macular oedema. Invest Ophthalmol Vis Sci 2004;45:1450-1455.
10. Stanga PE, Downes SM, Ahuja RM, Chong NH, Antcliff R, Reck AC, et al. Comparison of optical coherence tomography and fluorescein angiography in assessing macular oedema in retinal dystrophies: preliminary results. Int Ophthalmol 2001;23:321-325.
11. Chew EY, Ferris FL, Csaky KG, Murphy RP, Agrón E, Thompson DJS, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003;110:1683-1689.
12. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000;77:S113-S119. http://dx.doi.org/10.1046/j.1523-1755.2000.07718.x
13. Aiello LP, Edwards AR, Beck RW, Bressler NM, Davis MD, Ferris F, et al. Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular oedema. Ophthalmology 2010;117:946-953.
14. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular oedema: a randomised clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-3849.
15. Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular oedema: a systematic review. Ophthalmology 2009;116:902-911; quiz 912-913.
16. Cunningham ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, et al. A phase II randomised double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular oedema. Ophthalmology 2005;112:1747-1757.
17. Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, et al. A prospective randomised trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular oedema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-1086.e2.
18. Bolz M, Ritter M, Schneider M, Simader C, Scholda C, Schmidt-Erfurth U. A systematic correlation of angiography and high-resolution optical coherence tomography in diabetic macular oedema. Ophthalmology 2009;116:66-72.
19. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, et al. Safety and Efficacy of Ranibizumab in Diabetic Macular Oedema (RESOLVE Study). Diabetes Care 2010;33:2399-2405.
20. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al. Primary end point (six months) results of the ranibizumab for oedema of the macula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181.e1.
21. Nguyen QD, Shah SM, Khwaja A, Channa R, Hatef E, Do DV, et al. Two-year outcomes of the ranibizumab for oedema of the macula in diabetes (READ-2) study. Ophthalmology 2010;117:2146-2151.
22. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular oedema. Ophthalmology 2011;118:615-625.
23. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: World Health Organization; 1968.
24. Flach AJ. The incidence, pathogenesis and treatment of cystoid macular oedema following cataract surgery. Trans Am Ophthalmol Soc 1998;96:557-634.
25. Vestgaard M, Ringholm L, Laugesen CS, Rasmussen KL, Damm P, Mathiesen ER. Pregnancy-induced sight-threatening diabetic retinopathy in women with type 1 diabetes. Diabetic Med 2010;27:431-435. http://dx.doi.org/10.1111/j.1464-5491.2010.02958.x
26. Rossing K, Jacobsen P, Hommel E, Mathiesen E, Svenningsen A, Rossing P, et al. Pregnancy and progression of diabetic nephropathy. Diabetologia 2002;45:36-41. http://dx.doi.org/10.1007/s125-002-8242-4
27. Rasmussen KL, Laugesen CS, Ringholm L, Vestgaard M, Damm P, Mathiesen ER. Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes. Diabetologia 2010;53:1076-1083. http://dx.doi.org/10.1007/s00125-010-1697-9
28. Early Treatment for Diabetic Retinopathy Study Research Group. Early Treatment for Diabetic Retinopathy Study. Photocoagulation for diabetic macular oedema. Arch Ophthalmol 1985;103:1796-1806.
29. Browning DJ, Apte RS, Bressler SB, Chalam KV, Danis RP, Davis MD, et al. Association of the extent of diabetic macular oedema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. Retina 2009;29:300-305.
30. Philip S, Fleming AD, Goatman KA, Fonseca S, McNamee P, Scotland GS, et al. The efficacy of automated 'disease/no disease' grading for diabetic retinopathy in a systematic screening programme. Br J Ophthalmol 2007;91:1512-1517. http://dx.doi.org/10.1136/bjo.2007.119453
31. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997;13:388-391.
32. Polito A, Del Borrello M, Isola M, Zemella N, Bandello F. Repeatability and reproducibility of fast macular thickness mapping with stratus optical coherence tomography. Arch Ophthalmol 2005;123:1330-1337. http://dx.doi.org/10.1001/archopht.123.10.1330
33. Paunescu L. Reproducibility of nerve fibre thickness, macular thickness, and optic nerve head measurements using StratusOCT. Invest Ophthalmol Vis Sci 2004;45:1716-1724.
34. Carlton J, Karnon J, Smith KJ, Marr J. The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. Health Technol Assess 2008;12(25).
35. Scanlon PH, Foy C, Chen FK. Visual acuity measurement and ocular co-morbidity in diabetic retinopathy screening. Br J Ophthalmol 2008;92:775-778. http://dx.doi.org/10.1136/bjo.2007.128561
36. Liazos E, Broadbent DM, Beare N, Kumar N. Spontaneous resolution of diabetic macular oedema after discontinuation of thiazolidenediones. Diabet Med 2008;25:860-862. http://dx.doi.org/10.1111/j.1464-5491.2008.02491.x
37. Ambrosius WT, Danis RP, Goff DC, Greven CM, Gerstein HC, Cohen RM, et al. Lack of association between thiazolidinediones and macular oedema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol 2010;128:312-318.
38. Scottish Diabetic Retinal Screening Collaborative. Scottish Diabetic Retinopathy Grading Scheme 2007. 2007. URL: http://www.ndrs.scot.nhs.uk/ClinGrp/Docs/Grading_Scheme_2007_v1.1.pdf (accessed 13 April 2013).
39. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310. http://dx.doi.org/10.1016/j.ijnurstu.2009.10.001
40. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-160. http://dx.doi.org/10.1191/096228099673819272
41. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-428. http://dx.doi.org/10.1037//0033-2909.86.2.420
42. Brown H, Prescott R. Applied mixed models in medicine (statistics in practice). Hoboken, NJ: John Wiley & Sons; 2006.
43. Kish L. Survey sampling. New York, NY: John Wiley & Sons; 1965. pp. 424-426.
44. Bethlehem J. Weighting. In Lavrakas PJ, editor. The encyclopaedia of survey research methods. vol. 2. New York, NY: Sage; 2008. pp. 957-960.
45. Sapsford R. Survey research. London: Sage; 1999. pp. 31-32.
46. Warwick D, Lininger CA. The sample survey: theory and practice. New York, NY: McGraw-Hill; 1975. pp. 273-274.
47. Fleming AD, Goatman KA, Philip S, Prescott GJ, Sharp PF, Olson JA. Automated grading for diabetic retinopathy: a large-scale audit using arbitration by clinical experts. Br J Ophthalmol 2010;94:1606-1610. http://dx.doi.org/10.1136/bjo.2009.176784
48. Fleming AD, Goatman KA, Philip S, Williams GJ, Prescott GJ, Scotland GS, et al. The role of haemorrhage and exudate detection in automated grading of diabetic retinopathy. Br J Ophthalmol 2010;94:706-711. http://dx.doi.org/10.1136/bjo.2008.149807
49. Goatman K, Charnley A, Webster L, Nussey S. Assessment of automated disease detection in diabetic retinopathy screening using two-field photography. PLoS ONE 2011;6:e27524. http://dx.doi.org/10.1371/journal.pone.0027524
50. Fleming A, Philip S, Goatman K, Olson J, Sharp P. Automated microaneurysm detection using local contrast normalisation and local vessel detection. IEEE Trans Med Imaging 2006;25:1223-1232.
51. Fleming AD, Philip S, Goatman KA, Olson JA, Sharp PF. Automated assessment of diabetic retinal image quality based on clarity and field definition. Invest Ophthalmol Vis Sci 2006;47:1120-1125. http://dx.doi.org/10.1167/iovs.05-1155
52. Fleming AD, Philip S, Goatman KA, Olson JA, Sharp PF. Automated detection of exudates for diabetic retinopathy screening. Phys Med Biol 2007;52:331-345. http://dx.doi.org/10.1088/0031-9155/52/24/012
53. Fleming A, Goatman K, Philip S, Olson J, Sharp P. Automatic detection of retinal anatomy to assist diabetic retinopathy screening. Phys Med Biol 2007;52:331-345. http://dx.doi.org/10.1088/0031-9155/52/2/002
54. Fleming A, Goatman K, Williams G, Philip S, Sharp P, Olson J. Automated detection of blot haemorrhages as a sign of referable retinopathy. In McKenna S, Hoey J, editors. Proceedings of 12th Annual Conference on Medical Image Understanding and Analysis. Dundee; British Machine Vision Association; 2008. pp. 235-239.
55. HM Treasury. Green book guidance on discounting. URL: http://www.hm-treasury.gov.uk/green_book_guidance_discounting.htm (accessed 1 May 2013).
56. Personal Social Services Research Unit (PPSRU). Unit costs of health and social care 2010. Canterbury: PSSRU, University of Kent; 2010.
57. Department of Health. 2010. URL: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Managingyourorganisation/Financeandplanning/NHSFinancialReforms/index.htm (accessed 1 May 2013).
58. Information Services Division (ISD) Scotland. Specialty costs. 2010. URL: http://www.isdscotland.org/ Health-Topics/Finance/Costs/File-Listings-2010.asp (accessed 1 May 2013).
59. Department of Health. NHS reference costs 2009-2010. URL: http://www.gov.uk/government/publications/nhs-reference-costs-2009-2010 (accessed 1 May 2013).
60. National Institute for Health and Care Excellence (NICE). Macular oedema (diabetic): ranibizumab: final appraisal determination document. London: NICE; 2011.
61. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991;98(Suppl. 5):766-785.
62. Jyothi S, Sivaprasad S. Five-year visual outcome following laser photocoagulation of diabetic macular oedema. Eye 2011;25:850-859. http://dx.doi.org/10.1038/eye.2011.102
63. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabet Med 2008;25:618-24. http://dx.doi.org/10.1111/j.1464-5491.2008.02430.x
64. Early Treatment Diabetic Retinopathy Study research group. Early Treatment Diabetic Retinopathy Study (ETDRS). Photocoagulation for diabetic macular oedema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
65. Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA. Mortality in people with type 2 diabetes in the UK. Diabet Med 2006;23:516-521. http://dx.doi.org/10.1111/j.1464-5491.2006.01838.x
66. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia 2006;49:660-666. http://dx.doi.org/10.1007/s00125-005-0120-4
67. Younis N, Broadbent DM, Harding SP, Vora JP. Incidence of sight-threatening retinopathy in type 1 diabetes in a systematic screening programme. Diabet Med 2003;20:758-765. http://dx.doi.org/10.1046/j.1464-5491.2003.01035.x
68. Younis N, Broadbent DM, Vora JP, Harding SP. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003;361:195-200. http://dx.doi.org/10.1016/S0140-6736(03)12267-2
69. Aiello LP, Davis MD, Girach A, Kles KA, Milton RC, et al. PKC-DRS2 Group, Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006;113:2221-2230.
70. Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR, Group UKPDS (IKPDS). Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001;18:178-184.
71. Bhavsar KV, Subramanian ML. Risk factors for progression of subclinical diabetic macular oedema. Br J Ophthalmol 2011;95:671-674. http://dx.doi.org/10.1136/bjo.2010.182337
72. Varma R, Choudhury F, Klein R, Chung J, Torres M, Azen SP, et al. Four-year incidence and progression of diabetic retinopathy and macular oedema: the Los Angeles Latino Eye Study. Am J Ophthalmol 2010;149:752-753.
73. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M, et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009;32:2307-2313. http://dx.doi.org/10.2337/dc090615
74. Craig BA, Sendi PP. Estimation of the transition matrix of a discrete-time Markov chain. Health Econ 2002;11:33-42. http://dx.doi.org/10.1002/hec.654
75. Network DRCR. A randomised trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular oedema. Ophthalmology 2008;115:1447-1449; 1449.e1-10.
76. Network DRCR, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomised trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular oedema. Ophthalmology 2010;117:1064-1077.e35.
77. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular oedema. Ophthalmology 2011;118:609-614.
78. Hirai FE, Knudtson MD, Klein BE, Klein R. Clinically significant macular oedema and survival in type 1 and type 2 diabetes. Am J Ophthalmol 2008;145:700-706.
79. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201-1204. http://dx.doi.org/10.1136/bjo.87.10.1201
80. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17: 479-500. http://dx.doi.org/10.2165/00019053-200017050-00006
81. National Institute for Health and Care Excellence (NICE). Ranibizumab for the treatment of diabetic macular oedema. URL: http://guidance.nice.org.uk/TA237 (accessed 1 May 2013).
82. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889-896. http://dx.doi.org/10.1001/jama.283.7.889
83. Javitt JC, Aiello LP, Chiang Y, Ferris FL, 3rd, Canner JK, Greenfield S. Preventative eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994;17:909-917. http://dx.doi.org/10.2337/diacare.17.8.909
84. Davies R, Roderick P, Canning C, Brailsford S. The evaluation of screening policies for diabetic retinopathy using simulation. Diabet Med 2002;19:762-770. http://dx.doi.org/10.1046/j.1464-5491.2002.00773.x
85. James M, Turner DA, Broadbent DM, Vora J, Harding SP. Cost effectiveness analysis of screening for sight threatening diabetic eye disease. BMJ 2000;320:1627-1631. http://dx.doi.org/10.1136/bmj.320.7250.1627
86. Fercher AF. Optical coherence tomography - development, principles, applications. Zeitschrift fü r medizinische Physik 2010;20:251-276. http://dx.doi.org/10.1016/j.zemedi.2009.11.002
87. Virgili G, Menchini F, Dimastrogiovanni AF, Rapizzi E, Menchini U, Bandello F, et al. Optical coherence tomography versus stereoscopic fundus photography or biomicroscopy for diagnosing diabetic macular oedema: a systematic review. Invest Ophthalmol Vis Sci 2007;48:4963-4973.
88. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al. Optical coherence tomography. Science 1991;254:1178-1181. http://dx.doi.org/10.1126/science.1957169
89. Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris F. Detection of diabetic macular edema. Ophthalmoscopy versus photography - early treatment diabetic retinopathy study report number 5. The ETDRS Research Group. Ophthalmology 1989;96:746-750; discussion 750-751.
90. Davis MD, Gangnon RE, Lee L-Y, Hubbard LD, Klein BEK, Klein R, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123:1484-1498.
91. Zeimer R, Shahidi M, Mori M, Zou S, Asrani S. A new method for rapid mapping of the retinal thickness at the posterior pole. Invest Ophthalmol Vis Sci 1996;37:1994-2001.